220 related articles for article (PubMed ID: 28058217)
1. Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer.
Karadurmus N; Sahin U; Basgoz BB; Arpaci F; Demirer T
World J Transplant; 2016 Dec; 6(4):675-681. PubMed ID: 28058217
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
3. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-cancereffect and innovative approaches in thetreatment of refractory solid tumors.
Şahin U; Demirer T
Turk J Med Sci; 2020 Nov; 50(SI-2):1697-1706. PubMed ID: 32178508
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
Servais S; Baron F; Beguin Y
Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
Hwang YY; Mohty M; Chim CS
Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
[TBL] [Abstract][Full Text] [Related]
8. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
9. A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.
Atilla E; Ataca Atilla P; Demirer T
Balkan Med J; 2017 Jan; 34(1):1-9. PubMed ID: 28251017
[TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
11. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
12. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation for the treatment of advanced solid tumors.
Bregni M; Bernardi M; Ciceri F; Peccatori J
Springer Semin Immunopathol; 2004 Nov; 26(1-2):95-108. PubMed ID: 15378271
[TBL] [Abstract][Full Text] [Related]
14. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
Bishop MR; Fowler DH; Marchigiani D; Castro K; Kasten-Sportes C; Steinberg SM; Gea-Banacloche JC; Dean R; Chow CK; Carter C; Read EJ; Leitman S; Gress R
J Clin Oncol; 2004 Oct; 22(19):3886-92. PubMed ID: 15314059
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.
Hamadani M; Mohty M; Kharfan-Dabaja MA
Cancer Control; 2011 Oct; 18(4):237-45. PubMed ID: 21976242
[TBL] [Abstract][Full Text] [Related]
18. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
Espinoza-Delgado I; Childs RW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
[TBL] [Abstract][Full Text] [Related]
19. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
Maloney DG
Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
[TBL] [Abstract][Full Text] [Related]
20. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]